Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Once-Weekly Basal Insulin Analogue in Type 1 Diabetes

An annual report is the one IND submission that looks back across the whole year and arrives on a fixed date, and it differs in purpose from protocol amendments, information amendments, and IND safety reports. This article prepares the regulatory operations components of an annual report for a hypothetical open IND for a once-weekly basal insulin analogue studied in adults with type 1 diabetes in a 52-week, open-label Phase 3 study against a once-daily basal insulin (412 of 600 planned participants entered). It tabulates enrollment by age, sex, and race, summarizes severe hypoglycemia as the main known risk, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13, completes Form FDA 1571 as an academic specimen, and builds a timeline that accounts for year-end holidays before a January 30, 2027 deadline. A comparison table shows how the annual report differs from the other three IND submissions.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24420511
Primary Topic
Healthcare Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Once-Weekly Basal Insulin Analogue in Type 1 Diabetes

Peivand Pirouzi, Happy Makvana, Drashti Patel, Sahil Patel
Zenodo (CERN European Organization for Nuclear Research)
Healthcare Regulation
article

Annual Reporting Under an Open Investigational New Drug Application: Regulatory Operations and eCTD Submission Considerations for a Once-Weekly Basal Insulin Analogue in Type 1 Diabetes

Peivand Pirouzi, Happy Makvana, Drashti Patel, Sahil Patel
article en

Abstract

An annual report is the one IND submission that looks back across the whole year and arrives on a fixed date, and it differs in purpose from protocol amendments, information amendments, and IND safety reports. This article prepares the regulatory operations components of an annual report for a hypothetical open IND for a once-weekly basal insulin analogue studied in adults with type 1 diabetes in a 52-week, open-label Phase 3 study against a once-daily basal insulin (412 of 600 planned participants entered). It tabulates enrollment by age, sex, and race, summarizes severe hypoglycemia as the main known risk, maps each paragraph of 21 C.F.R. 312.33 to Module 1.13, completes Form FDA 1571 as an academic specimen, and builds a timeline that accounts for year-end holidays before a January 30, 2027 deadline. A comparison table shows how the annual report differs from the other three IND submissions.Keywords: IND annual report; 21 C.F.R. 312.33; eCTD Module 1.13; regulatory operations; Form FDA 1571; submission lifecycle

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Healthcare Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon